Posted on Dec 30, 2023
A popular asthma inhaler is leaving pharmacy shelves. Here's what you need to know
1.12K
16
3
8
8
0
https://www.npr.org/sections/health-shots/2023/12/30/ [login to see] /a-popular-asthma-inhaler-is-leaving-pharmacy-shelves-heres-what-you-need-to-know
Some asthma patients may start out the new year scrambling for their go-to inhaler – at least that's the concern as Flovent, a popular drug, leaves store shelves starting in January.
Earlier this year, drugmaker GSK announced it's discontinuing Flovent in 2024. There is a generic version to take its place, but some doctors worry patients could be left in the lurch as they sort out how to get the new medication covered by insurance.
Some asthma patients may start out the new year scrambling for their go-to inhaler – at least that's the concern as Flovent, a popular drug, leaves store shelves starting in January.
Earlier this year, drugmaker GSK announced it's discontinuing Flovent in 2024. There is a generic version to take its place, but some doctors worry patients could be left in the lurch as they sort out how to get the new medication covered by insurance.
A popular asthma inhaler is leaving pharmacy shelves. Here's what you need to know
Posted from npr.org
Medical
Health
Drugs
Pharmaceuticals
Posted 5 mo ago
Responses: 3
4
4
0
PO1 William "Chip" Nagel good day Brother William, always informational and of the most interesting. Thanks for sharing, have a blessed day!
(4)
(0)
3
3
0
PO1 William "Chip" Nagel
..."AIRSUPRA is a combination of albuterol, a beta2-adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older."
..."AIRSUPRA is a combination of albuterol, a beta2-adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older."
(3)
(0)
1
1
0
Read This Next
Continue with Facebook 
Continue with Google